Innate lymphoid cells for cell therapy and biomarkers therefor
AssigneeUniversity Health Network
InventorsSarah CROME, Kyle REID, Jessica MATHEWS, Julia MURPHY, Sarah COLPITTS
Life of this patent
Estimating the term…
Abstract
There is described herein methods of ameliorating, treating or preventing graft-versus-host disease, transplant rejection or an autoimmune disorder, or promoting transplant graft function in a human using innate lymphoid cells (ILCs), including compositions comprising ILCs and methods for making the same.
Claims24
A method of ameliorating, treating or preventing graft-versus-host disease, transplant rejection or an autoimmune disorder, or promoting transplant graft function in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a population of cells comprising innate lymphoid cells (ILCs).
(canceled)
(canceled)
A method for inducing a population of regulatory innate lymphoid cells, (ILCregs) from innate lymphoid cell (ILC) precursors and/or NK cells, and the method comprising culturing the population with at least one of TGF-β, IL-2 and anti-IFN-γ.
22-30. (canceled)
A method of selecting from a population of cells comprising innate lymphoid cells (ILCs), those cells that are ILC2 cells by selecting for cells that are CD45+, CD127+, CRTh2+ and CD3−, CD4−, CD8−, CD14−, CD15−, CD19−, CD20−, CD33−, CD34−, CD68−, CD138−, CD203c−, FCεRI−, TCRαβ−, TCRγδ—, IgA−, CD16−,CD94−, NKG2D−, CCR6− and NKp44−.
32-46. (canceled)
Dependencies are inferred from the claim text.